FDA Approves New Chemical Abortion Drug Amid Concerns
Senator Josh Hawley from Missouri has criticized the Food and Drug Administration (FDA) for approving another chemical abortion drug without a comprehensive safety review, citing risks to women’s health. He emphasized the weak regulatory framework and pointed out that the company involved failed to adequately define “women” in its materials.
Hawley expressed his shock on social media, stating, “It’s alarming that the FDA has authorized another chemical abortion drug when we know these drugs can be dangerous, even fatal for mothers; and, of course, they are lethal for unborn children.” He also mentioned that he has lost trust in the FDA’s leadership regarding their commitment to safety reviews of these drugs.
Prolife Group Calls for Senate Action
A prolife organization has urged the Senate to enforce protection measures addressing the safety of abortion drugs. This comes as Evita Solutions aims to normalize abortion and expand access, claiming that safe and effective abortion care should be available to everyone without discrimination.
According to a letter sent on September 30th, the FDA approved Evita’s drug, which sparked further concerns from Hawley. In an interview with Fox News Digital, he admitted to being baffled by the FDA’s actions, noting that promised safety reviews have barely begun.
“I’m really trying to make sense of what is happening with the FDA,” Hawley remarked, revealing his confusion about the situation.
Debate Over Safety and Accessibility
Evita is collaborating with Genbiopro to produce a generic version of Mifepristone, the first drug used in a medical abortion. Mifepristone blocks progesterone, which is necessary for maintaining a pregnancy, and is followed by misoprostol to complete the procedure. This approval arrives amidst increasing opposition from conservative lawmakers and religious organizations who are questioning the safety and accessibility of abortion drugs.
Despite this, organizations like Inspire Investing and Alliance Defending Freedom are fighting against Mifepristone, while others like the America Foundation (ROAF) are calling for accountability from legislators. Recently, ROAF urged the Senate Finance Committee to ensure that safety measures remain in place, voicing concerns about potential vulnerabilities for women and costs to taxpayers associated with the removal of safety protocols for abortion drugs like Mifepristone.
Hawley believes that the FDA should revert to safety procedures that were set during the Trump administration, advocating for a return to stricter regulations. “The FDA needs to restore the safeguards that were put in place. We should pivot away from the current approach and return to what was established previously,” he stated.
During the Biden administration, the FDA has permitted mail-order prescriptions for abortion drugs, a shift from previous practices where distribution was more controlled to monitor for complications.
